BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FemmePharma, Inc. Appoints Ernst & Young As Company's Independent Auditors


10/19/2005 5:11:20 PM

WAYNE, PA, July 30, 2004 –FemmePharma, Inc. announced today its Board of Directors has approved the selection of Ernst & Young as the Company’s independent auditors. “After reviewing several firms, we are confident the world-wide experience and reputation Ernst & Young brings will provide FemmePharma with an excellent partner as it continues to execute its business strategy,” said Kevin Flanagan, a Director of the Company and Chairman of its Audit Committee.

About FemmePharma, Inc.

FemmePharma was founded by Gerianne Tringali DiPiano in 1996 to target needs within the estimated $70 billion women’s healthcare pharmaceutical market. The Company is in a Phase III trial for FP1096, a new investigational treatment for endometriosis, and is preparing for its Phase II trial for its drug to treat female urinary incontinence.

FemmePharma is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman’s physiology, with an eye toward the changing needs of women throughout their lives. The company has a number of drugs in development based on its proprietary technologies, including a new therapeutic option for mastalgia. For more information about FemmePharma, please visit its website at www.femmepharmainc.com.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->